Poging GOUD - Vrij
30 COVID-19 Vaccine Projects Afoot In India
Bio Spectrum
|July 2020
When it comes to India that produces 60 per cent of the world’s vaccines and accounts for 60-80 per cent of the United Nations’ annual vaccine procurement, development of a new vaccine is a major task. But what works in India’s favour in the race for a vaccine is that a number of Indian firms are key players in the global vaccine industry. So, along with employing different technology platforms for vaccine development, India has adopted a cross-functional collaborative approach, globally and locally, wherein currently 30 vaccine projects are afoot against COVID-19.
-
Researchers world over are working around the clock to find a vaccine against SARS-CoV-2, the virus causing the COVID-19 pandemic. Experts estimate that a fast-tracked vaccine development process could speed a successful candidate to market in approximately 12-18 months if the process goes smoothly from conception to market availability.
A striking feature of the vaccine development landscape for COVID-19 is the range of technology platforms being evaluated, including nucleic acid (DNA and RNA), virus-like particle, peptide, viral vector (replicating and non-replicating), recombinant protein, live attenuated virus and inactivated virus approaches.
The interesting part is that many of these platforms are not currently the basis for licensed vaccines. For example, globally there are no approved mRNA or DNA vaccines, and neither have ever been tested in a large-scale clinical trial for an infectious disease.
Now, when it comes to India that produces 60 per cent of the world’s vaccines and accounts for 60-80 per cent of the United Nations’ annual vaccine procurement, development of a new vaccine using a new technology is a major task. Back in 2014, Rotavac vaccine was the first to be conceived and developed from scratch in India.
India has so far not been at the forefront of developing vaccines, but what works in India’s favour in the race for a vaccine is that a number of Indian firms are key players in the global vaccine industry. So, along with employing different technology platforms for vaccine development, India has adopted a cross-functional collaborative approach, globally and locally, wherein currently 30 vaccine projects are afoot against COVID-19.
Dit verhaal komt uit de July 2020-editie van Bio Spectrum.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN Bio Spectrum
Bio Spectrum
MAHE teams up with OpenAI to integrate AI to enhance outcomes
Manipal Academy of Higher Education (MAHE), an Institution of Eminence Deemed to be University in Karnataka, has partnered with OpenAI to integrate advanced artificial intelligence (AI) tools across teaching, research, and academic administration.
1 min
April 2026
Bio Spectrum
Jubilant Bhartia Foundation & McGill University to launch CoE in AI education
The Jubilant Bhartia Foundation in collaboration with McGill University (Canada), has signed a Memorandum of Understanding (MoU) to create the Centre of Excellence (CoE) in artificial intelligence (AI) Education and Research.
1 min
April 2026
Bio Spectrum
Heeding Auditory Warning Signs
By 2050, nearly 2.5 billion people are projected to have some degree of hearing loss, and more than 700 million might require hearing rehabilitation. That's according to the World Health Organization (WHO).
2 mins
April 2026
Bio Spectrum
Botanic Healthcare on-boards Narahari Naidu as Group Chief Financial Officer
Secundarabad-based Botanic Healthcare, a globally leading nutraceutical company, has announced the appointment of Narahari Naidu as its Group Chief Financial Officer (CFO).
1 min
April 2026
Bio Spectrum
Paras Health ropes in Balkishan Sharma as Group CHRO and Business Transformation Officer
Paras Health has announced the appointment of Balkishan Sharma as Group Chief Human Resources Officer (Group CHRO) and Business Transformation Officer.
1 min
April 2026
Bio Spectrum
Parse Biosciences unveils Evercode Whole Transcriptome V4 with shorter workflow
Parse Biosciences, a Qiagen company, has announced the launch of the new Evercode Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers
1 min
April 2026
Bio Spectrum
UK deploys new bone scanners to help prevent fractures
Tens of thousands of patients at risk of osteoporosis and other bone conditions will get faster access to vital bone scans, as 20 new scanners are rolled out across England.
1 min
April 2026
Bio Spectrum
Cytiva expands Fast Trak process development and validation services facility in India
Cytiva, a Danaher company and a leader in the life sciences industry, has inaugurated an expanded facility for Fast Trak process development (PD) and validation services in Bengaluru.
1 min
April 2026
Bio Spectrum
ΑΙ TAKES INDIAN PHARMA REINS
The Indian pharmaceutical sector, one of the largest in the world, is undergoing a strategic transformation in the way it operates. As artificial intelligence (AI) gains prominence across the industry, companies are actively adopting Al-driven solutions to enhance efficiency across the entire pharmaceutical ecosystem. Organisations are investing in AI training programmes to keep their workforce future-ready, foster innovation, strengthen supply chains, and transition away from manual record-keeping. In this industry analysis, experts share their perspectives on how AI is shaping the future of the pharma sector.
10 mins
April 2026
Bio Spectrum
NIH halts arm of clinical trial evaluating potential stroke treatment
The National Institutes of Health (NIH) in the US has stopped an investigational treatment arm of the Comparison of Anti-coagulation and Anti-platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) study, following a regular review by the Data Safety and Monitoring Board (DSMB).
1 min
April 2026
Translate
Change font size
